PIAS4: A Promising Drug Target and Biomarker for STAT-Mediated Signaling

Target Name: PIAS4

NCBI ID: G51588

PIAS4

PIAS4: A Promising Drug Target and Biomarker for STAT-Mediated Signaling

Protein inhibitors of activated STAT protein gamma (PIAS4) have the potential to disrupt the complex signaling cascades that regulate various cellular processes.STAT proteins are involved in regulating cytoskeletal organization, DNA replication, and inflammation. Activated STAT proteins are highly activated forms of these proteins that play a crucial role in cellular responses to stress and damage. In this article, we will explore the potential implications of PIAS4 as a drug target and biomarker.

Understanding PIAS4

PIAS4 is a non-coding RNA molecule that belongs to the PIAS family of proteins. These proteins are known for their ability to inhibit the activity of transcription factors, such as STAT proteins, which play a crucial role in regulating cellular processes. PIAS4 is expressed in various tissues and cells, including muscle, heart, and brain.

PIAS4 functions as a negative regulator of STAT3, which is a key transcription factor that regulates various cellular processes, including cell growth, differentiation, and inflammation. In cooperation with STAT3, PIAS4 promotes the negative control of cellular processes by inhibiting the activity of STAT3.

Drug Target Potential

The inhibition of PIAS4 by small molecules has the potential to disrupt the signaling cascades that are regulated by STAT3. This could lead to a range of cellular responses, including the inhibition of cellular processes that are critical for the survival and growth of cancer cells, as well as the regulation of cellular immune responses.

In addition to its potential therapeutic applications, the inhibition of PIAS4 by small molecules could also serve as a biomarker for the assessment of STAT3 signaling activity. The levels of PIAS4 expression and its inhibition by small molecules could be used as indicators of the effectiveness of a given drug or treatment.

Biomarker Potential

The PIAS4 gene has been shown to be involved in a variety of cellular processes, including the regulation of cell growth, differentiation, and the response to stress and damage. Studies have also demonstrated that PIAS4 is involved in the regulation of cellular signaling pathways, including the TGF-灏? pathway.

In addition to its role in cellular signaling, PIAS4 has also been shown to play a role in the regulation of cellular immune responses. For example, PIAS4 has been shown to be involved in the regulation of the development and function of natural killer cells, which are a crucial part of the immune system.

Conclusion

In conclusion, PIAS4 is a promising drug target and biomarker for the regulation of cellular processes that are regulated by STAT3. The inhibition of PIAS4 by small molecules has the potential to disrupt the complex signaling cascades that are regulated by STAT3, leading to a range of cellular responses. Further research is needed to fully understand the role of PIAS4 in cellular processes and its potential as a drug target and biomarker.

Protein Name: Protein Inhibitor Of Activated STAT 4

Functions: Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor (PubMed:12511558, PubMed:12631292, PubMed:12727872, PubMed:15831457, PubMed:15976810, PubMed:22508508, PubMed:32832608). Mediates sumoylation of CEBPA, PARK7, HERC2, MYB, TCF4 and RNF168 (PubMed:12511558, PubMed:12631292, PubMed:12727872, PubMed:15831457, PubMed:15976810, PubMed:22508508). Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway, the p53/TP53 pathway, the Wnt pathway and the steroid hormone signaling pathway (PubMed:11388671). Involved in gene silencing (PubMed:11248056). In Wnt signaling, represses LEF1 and enhances TCF4 transcriptional activities through promoting their sumoylations (PubMed:12727872, PubMed:15831457). Enhances the sumoylation of MTA1 and may participate in its paralog-selective sumoylation (PubMed:21965678). Binds to AT-rich DNA sequences, known as matrix or scaffold attachment regions (MARs/SARs) (By similarity). Catalyzes conjugation of SUMO2 to KAT5 in response to DNA damage, facilitating repair of DNA double-strand breaks (DSBs) via homologous recombination (HR) (PubMed:32832608). Mediates sumoylation of PARP1 in response to PARP1 trapping to chromatin (PubMed:35013556)

The "PIAS4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PIAS4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets